HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?
Journal
Hepatology
Journal Volume
67
Journal Issue
4
Pages
1634-1635
Date Issued
2018
Author(s)
SDGs
Other Subjects
circular DNA; covalently closed circular DNA; entecavir; unclassified drug; antivirus agent; alcohol liver disease; antiviral therapy; cancer incidence; cancer patient; cancer risk; chronic hepatitis B; Hepatitis B virus; human; Letter; liver cell; liver cell carcinoma; liver cirrhosis; mortality rate; patient risk; priority journal; treatment duration; vaccination; virus replication; chronic hepatitis B; Hepatitis B virus; liver cell carcinoma; liver tumor; treatment outcome; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Treatment Outcome
Publisher
John Wiley and Sons Inc.
Type
letter